PRTG - Portage Biotech Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Tortola,
British Virgin Islands
Type: Equity
PRTG price evolution
PRTG
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $0.09 | $0.1 | $0.16 | |
| Inventory | ||||
| Total current assets | $5.2 | $7.7 | $7.52 | |
| Long term investments | ||||
| Property, plant & equipment | $0.03 | $0.04 | $0.26 | |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $5.24 | $7.78 | $49.03 | |
| Current liabilities | ||||
| Accounts payable | $1.48 | $2.84 | $2.66 | |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $3 | $2.88 | $2.71 | |
| Long term debt | $0.01 | $0.23 | ||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $2.73 | $3.76 | $17.04 | |
| Shareholders' equity | ||||
| Retained earnings | -$216.99 | -$215.48 | -$186.61 | |
| Other shareholder equity | -$0.88 | |||
| Total shareholder equity | ||||
| (in millions $) | 1 May 2024 | 1 May 2023 | 1 May 2022 | 30 Apr 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2.77 | |||
| Short term investments | ||||
| Net receivables | $0.1 | $0.8 | $0.35 | $0.68 |
| Inventory | ||||
| Total current assets | $7.7 | $13.68 | $24.83 | $4.95 |
| Long term investments | ||||
| Property, plant & equipment | $0.04 | |||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $169.91 | |||
| Total investments | ||||
| Total assets | $7.78 | $99.13 | $194.66 | $174.86 |
| Current liabilities | ||||
| Accounts payable | $2.84 | $0.27 | $0.19 | $1.94 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $2.88 | $1.86 | $0.78 | $3.21 |
| Long term debt | $0.01 | |||
| Total noncurrent liabilities | $24.05 | |||
| Total debt | ||||
| Total liabilities | $3.76 | $23.08 | $73.46 | $27.26 |
| Shareholders' equity | ||||
| Retained earnings | -$215.48 | -$138.41 | -$38.08 | -$38.13 |
| Other shareholder equity | -$4.33 | $0.96 | $55.09 | |
| Total shareholder equity | ||||
| (in millions $) | 30 Jul 2025 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $2.85 | $3.26 | $4.04 | |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0 | $0 | -$9.5 | |
| Interest expense | $0.04 | $0.8 | -$0.06 | |
| Net income | ||||
| Net income | -$1.66 | -$24.89 | -$39.37 | |
| Income (for common shares) | ||||
| (in millions $) | 1 May 2024 | 1 May 2023 | 1 May 2022 | 30 Apr 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $18.25 | $16.57 | $15.59 | $12.44 |
| Operating income | -$12.44 | |||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$10.55 | -$17.86 | $4.35 | $2.3 |
| Interest expense | $0.77 | -$0.07 | $0.77 | $0.18 |
| Net income | ||||
| Net income | -$75.34 | -$104.61 | -$16.87 | -$15.83 |
| Income (for common shares) | ||||
| (in millions $) | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 | 30 Oct 2023 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $2.81 | |||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$0.01 | $5.97 | $5.97 | $0.65 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$1.69 | -$5.52 | -$5.2 | -$7.1 |
| (in millions $) | 1 May 2024 | 1 May 2023 | 1 May 2022 | 30 Apr 2021 |
|---|---|---|---|---|
| Net income | -$17.19 | |||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$4.28 | |||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $2.81 | -$0.62 | -$0.86 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $5.97 | -$0.12 | $27.35 | $4.76 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$5.52 | -$12.81 | $20.58 | -$0.38 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | N/A |
| Quick ratio | N/A |